Close menu

October 17th, 2022 | 12:21 CEST

Defence Therapeutics, Commerzbank - Like BioNTech in March 2020?

  • Biotechnology
  • Turnaround
Photo credits:

After price shocks and recession fears, the pandemic has also been back in the public eye since last week. German Health Minister Karl Lauterbach presented the vaccination strategy for the fall - and warned of an autumn wave. On the markets, the pandemic should be over, with a few exceptions. But Corona and BioNTech are suitable blueprints for other companies. We explain where else a special boom could occur and where investors are better off being cautious.

time to read: 4 minutes | Author: Nico Popp

Table of contents:

    David Elsley, CEO, Cardiol Therapeutics Inc.
    "[...] As a company dedicated to developing treatments for rare heart diseases, we see this as an opportune moment to contribute to the fight against heart disease and make meaningful strides in improving heart health worldwide. [...]" David Elsley, CEO, Cardiol Therapeutics Inc.

    Full interview


    BioNTech: Between vaccine strategy and cancer fantasy

    As share prices worldwide plummeted in March 2020, the strategists behind BioNTech were working on the Company's future. Despite the general doom and gloom, a huge opportunity opened up for BioNTech. The mRNA technology they had long been researching was suddenly in demand like never before. The desire for fast and effective vaccines was great. In the US, then-US President Donald Trump made possibly the best decision of his time in office: he declared the search for a vaccine the country's most important mission - no matter what the cost. Because of this support, Pfizer and BioNTech were able to develop their Corona vaccine quickly. Where the typical process involves pausing and gradually injecting capital depending on details, Pfizer and BioNTech have been able to draw on their full resources.

    In Germany, another vaccination campaign is currently underway. People over 60 and those with previous illnesses can get their 4th shot. Vaccines have now been developed expressly for the Omicron variant. This new demand for vaccines should have a positive impact on BioNTech. However, the great vaccination hype is over. Shareholders can still rejoice: BioNTech recently opened a subsidiary in Australia, where it plans to conduct more research into vaccines against cancer. The cash flow from the Corona vaccines will therefore be invested for growth. The share has stabilized in recent months and could rise again in the medium term. However, BioNTech is no longer an insider tip.

    Defence Therapeutics facing months of truth

    The situation is quite different for the Canadian company Defence Therapeutics. The biotech company has a broad range of active ingredients and active ingredient enhancers that can be used in various ways. They recently announced a clinical trial for the active ingredient AccuTOX™ to fight lung cancer. What is unique about the pre-clinical study is that the compound will be administered intranasally to then act in the lungs. The active ingredient AccuTOX™, for which Defence Therapeutics has filed a patent application, is an offshoot of the Accum™ technology, which has been known for some time. In short, the aim is to channel various active ingredients more effectively into the cell nucleus and thus achieve greater effects. Defence Therapeutics is using this process to research vaccines against various cancer types, including skin and cervical cancer. Clinical trials are scheduled to start in early 2023.

    Since Accum™ can be used very flexibly as a drug booster, it is also conceivable that the technology will help other active ingredients that have already been discarded in clinical trials to make a comeback. The first phase of clinical trials is all about the safety of active ingredients. If this is not the case, the trial fails. If the dose can be drastically reduced thanks to active ingredient boosters, previously failed projects could be given a new lease of life. Investors can also recognize "fresh blood" when they look at the performance of the Defence Therapeutics share. The value has recovered recently but is still cheap. It will be crucial for the Company to be able to implement its plans. Given the versatility of the technology and the numerous opportunities, knowledgeable investors should already have the Company on their radar. Defence Therapeutics is currently comparable to BioNTech before COVID-19 was declared a pandemic - only industry insiders have the value on their radar. However, this should change as soon as scientific perspectives turn into concrete market opportunities. The stock is speculative but also about 80% cheaper than a year ago. In addition, operational progress is imminent. Defence Therapeutics is anything but uninteresting!

    Commerzbank: Interest rate turnaround positive, real estate market negative!

    The same applies to the Commerzbank share. The Frankfurt share price has remained stable in recent weeks despite the challenging market environment. As we recall, at times, there was even talk of a new banking quake. However, these speculations have left the yellow bank cold. However, trouble is looming in the real estate business. As Savings Bank President Helmut Schleweis told the Handelsblatt, many real estate projects in the planning stage are currently being put on hold again. Also, many private prospective customers simply could not afford real estate any longer - the mortgage interest multiplied in 2022. At the same time, inflation and a shortage of materials are weighing on construction and renovation. Commerzbank recently benefited from the bear market rally. However, many construction sites still remain. Between EUR 8.20 and EUR 8.40, the share must show what it can do. If the breakout above this level fails, it can also go down again.

    Even though many banks have been eagerly awaiting the turnaround in interest rates, higher interest rates are anything but a special boom. The distortions in the current situation are too great. On the other hand, stocks that can do well in any market are BioNTech or even Defence Therapeutics. Whoever develops the next blockbuster is guaranteed to leave inflation and crisis behind. While BioNTech is already an old hand in the business, Defence Therapeutics still has the aura of a newcomer. In addition, there are the many projects and the opportunity for licensing income if, for example, the patented active ingredient enhancer were to be made available to other companies. The coming months are likely to be exciting.

    Conflict of interest

    Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.

    In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.

    For this reason, there is a concrete conflict of interest.

    The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.

    Risk notice

    Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.

    The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.

    The acquisition of financial instruments involves high risks, which can lead to the total loss of the invested capital. The information published by Apaton Finance GmbH and its authors is based on careful research. Nevertheless, no liability is assumed for financial losses or a content-related guarantee for the topicality, correctness, appropriateness and completeness of the content provided here. Please also note our Terms of use.

    Der Autor

    Nico Popp

    At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.

    About the author

    Related comments:

    Commented by Juliane Zielonka on April 12th, 2024 | 07:00 CEST

    AI in healthcare with Evotec, Defence Therapeutics, Bayer: Revolutionary advances and medical breakthroughs

    • Biotechnology
    • Pharma
    • AI

    Artificial intelligence (AI) is gaining momentum in the healthcare sector. AI-based systems can use medical databases to save valuable time in research, enabling companies like Defence Therapeutics to go to market faster than others. In oncology research, the Canadian company has just achieved a breakthrough that gives hope to many cancer patients. AI-assisted diagnoses allow diseases to be detected earlier and treated more effectively, leading to improved quality of life for patients. Precision medicine in strong partnership networks is Evotec's focus. The share is particularly popular with hedge fund managers. Analyzing medical images and data in real-time and detecting even the smallest deviations or anomalies is the top priority for Bayer AG in collaboration with Google Cloud. Which companies are convincing investors the most?


    Commented by Fabian Lorenz on April 10th, 2024 | 07:00 CEST

    BASF and Cardiol Therapeutics recommended to buy! TUI share with momentum!

    • Biotechnology
    • Cancer
    • travel
    • chemicals

    BASF shares have gained over 30% within six months. But is the rally in BASF shares slowly running out of steam? The fact that the share did not rise sharply yesterday despite a significant price target increase suggests this is the case. Many experts see little potential for further price increases. The situation is different for the biotech company Cardiol Therapeutics. The analysts at Canaccord believe that the shares of the specialist in cardiovascular diseases could perform by around 200%. Financing is secured until 2026, and important study data is due in the current quarter. The TUI share has been on a roll for several months now. Will the share continue to rise with the increase in temperatures? Management is certainly optimistic about the future.


    Commented by André Will-Laudien on April 10th, 2024 | 06:45 CEST

    Attention: Biotech takeovers, after MorphoSys, now Bayer, Vidac Pharma, BioNTech and Pfizer are on the radar

    • Pharma
    • Biotechnology
    • Innovations

    Since the onset of the COVID-19 pandemic, there has been little movement in the biotech sector. However, after a challenging year in 2023, the sector was at least able to start the new year on a solid footing. The surprising takeover of MorphoSys recently got hearts beating again, as Novartis put a whopping EUR 2.7 billion on the table for the cancer specialist from Munich. Only months before, MorphoSys had been traded on the stock exchange at just EUR 700 million. The special market situation in this case was also characterized by the high short ratio, which led to an exorbitant rise in the share price of almost 400% in the final phase. Speculative investors are now keeping a wary eye on potential takeover candidates as the sector is once again attracting considerable attention. We are taking a closer look and searching for the next pearl.